person

Nils Morten L.

Country
Norway
Department
Department of Hematology

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
116
Sites with multiple studies

Has run more than one trial at 116 of 189 partner sites.

Specializations

Hematologic Malignancies

This investigator specializes in the treatment of multiple myeloma, focusing on innovative approaches to disease monitoring and treatment timing. Their research explores the clinical significance of minimal residual disease (MRD) assessment in treatment decisions.

  • Multiple Myeloma Management
  • MRD Monitoring Strategies
  • Early Intervention Protocols

The investigator's work addresses critical timing of therapeutic interventions in relation to disease progression markers.

Leukemia and Myelodysplastic Syndromes

The investigator conducts research in acute myeloid leukemia (AML) and myelodysplastic syndrome treatments. Their work involves evaluating novel therapeutic combinations for newly diagnosed patients.

  • AML Treatment Optimization
  • Novel Drug Combinations
  • Induction Therapy Approaches

Their research focuses on improving treatment outcomes through targeted therapeutic strategies in hematologic malignancies.

Autoimmune Hematologic Disorders

The investigator specializes in treating immune thrombocytopenia (ITP), exploring comparative effectiveness of different therapeutic approaches. Their research examines various treatment options for patients who don't respond to initial therapy.

  • ITP Management Strategies
  • Second-line Treatment Options
  • Thrombopoietin Receptor Agonist Therapy

The work encompasses evaluation of oral medications and targeted antibody treatments in autoimmune blood disorders.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.